BioNTech Fills Coffers With Extra $325m Via Series B Financing

Mainz-based BioNTech raises $325m in an upsized series B round to further advance its individualized immuno-oncology pipeline and manufacturing infrastructure.

US dollars

With press reports elsewhere announcing that BioNTech AG, the Mainz, Germany-based biotech, was hiring banks to pursue an $800m IPO, for a post-money valuation approaching $4bn, the company has instead opted to raise additional venture financing through an upsized series B round of $325m. The company says the funds will be used to support the continued development of its therapeutics pipeline and manufacturing infrastructure as it strives to become of fully integrated biopharmaceutical company.

“We have always communicated that we will look at all financing options and we will continue this evaluation moving forward....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip